Charter Renewal for the Advisory Committee on Organ Transplantation, 54224 [2022-18963]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
54224
Federal Register / Vol. 87, No. 170 / Friday, September 2, 2022 / Notices
enough to provide timely notice.
Therefore, you should always check the
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. On October
28, 2022, the committee will discuss
biologics license application 761176, for
131 I-omburtamab solution for injection,
submitted by Y-mAbs Therapeutics, Inc.
The proposed indication (use) for this
product is for the treatment of
neuroblastoma with central nervous
system/leptomeningeal metastases.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link. The meeting will include slide
presentations with audio components to
allow the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see ADDRESSES) on or before
October 14, 2022, will be provided to
the committee. Oral presentations from
the public will be scheduled between
approximately 1 p.m. to 2 p.m. Eastern
Time. Those individuals interested in
making formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before October 5, 2022. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
VerDate Sep<11>2014
16:40 Sep 01, 2022
Jkt 256001
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by October 6, 2022.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Philip Bautista
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 29, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–19047 Filed 9–1–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Charter Renewal for the Advisory
Committee on Organ Transplantation
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act
(FACA), HHS is hereby giving notice
that the Advisory Committee on Organ
Transplantation (ACOT or Committee)
has been renewed. The effective date of
the charter renewal is August 31, 2022.
FOR FURTHER INFORMATION CONTACT:
Shelley Tims Grant (Designated Federal
Officer); HRSA Division of
Transplantation, HRSA, 5600 Fishers
Lane, 08W67, Rockville, Maryland
20857; 301–443–8036; or sgrant@
hrsa.gov.
SUMMARY:
ACOT
provides advice and recommendations
to the Secretary of HHS (Secretary) on
policy, program development, and other
matters of significance concerning the
activities pursuant to 42 U.S.C. 217a;
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
section 222 of the Public Health Service
Act. ACOT may provide advice to the
Secretary on proposed Organ
Procurement and Transplantation
Network policies and such other matters
as the Secretary determines.
The renewed charter for ACOT was
approved on August 25, 2022. The filing
date of the renewed charter is August
31, 2022. The renewal of the ACOT
charter gives authorization for the
committee to operate until August 31,
2024.
A copy of the ACOT charter is
available on the ACOT website at
https://www.hrsa.gov/advisorycommittees/organ-transplantation. A
copy of the charter can also be obtained
by accessing the FACA database that is
maintained by the Committee
Management Secretariat under the
General Services Administration. The
website address for the FACA database
is https://www.facadatabase.gov/.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–18963 Filed 9–1–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Tick-Borne Disease
Working Group
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As required by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the Tick-Borne Disease Working
Group (TBDWG) will hold a meeting.
The meeting will be open to the public
via webcast. For this meeting, the
TBDWG will (1) review the final draft of
chapters for the report and (2) further
discuss plans for developing the next
report to the HHS Secretary and
Congress on federal tick-borne activities
and research, taking into consideration
the 2018 and 2020 report. The 2022
report will address a wide range of
topics related to tick-borne diseases,
such as, surveillance, prevention,
diagnosis, diagnostics, and treatment;
identify advances made in research, as
well as overlap and gaps in tick-borne
disease research; and provide
recommendations regarding any
appropriate changes or improvements to
such activities and research.
DATES: The public can view the meeting
online via webcast on October 4–5, 2022
SUMMARY:
E:\FR\FM\02SEN1.SGM
02SEN1
]]>Agencies
[Federal Register Volume 87, Number 170 (Friday, September 2, 2022)]
[Notices]
[Page 54224]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18963]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Charter Renewal for the Advisory Committee on Organ
Transplantation
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act (FACA),
HHS is hereby giving notice that the Advisory Committee on Organ
Transplantation (ACOT or Committee) has been renewed. The effective
date of the charter renewal is August 31, 2022.
FOR FURTHER INFORMATION CONTACT: Shelley Tims Grant (Designated Federal
Officer); HRSA Division of Transplantation, HRSA, 5600 Fishers Lane,
08W67, Rockville, Maryland 20857; 301-443-8036; or [email protected].
SUPPLEMENTARY INFORMATION: ACOT provides advice and recommendations to
the Secretary of HHS (Secretary) on policy, program development, and
other matters of significance concerning the activities pursuant to 42
U.S.C. 217a; section 222 of the Public Health Service Act. ACOT may
provide advice to the Secretary on proposed Organ Procurement and
Transplantation Network policies and such other matters as the
Secretary determines.
The renewed charter for ACOT was approved on August 25, 2022. The
filing date of the renewed charter is August 31, 2022. The renewal of
the ACOT charter gives authorization for the committee to operate until
August 31, 2024.
A copy of the ACOT charter is available on the ACOT website at
https://www.hrsa.gov/advisory-committees/organ-transplantation. A copy
of the charter can also be obtained by accessing the FACA database that
is maintained by the Committee Management Secretariat under the General
Services Administration. The website address for the FACA database is
https://www.facadatabase.gov/.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022-18963 Filed 9-1-22; 8:45 am]
BILLING CODE 4165-15-P
